Less Ads, More Data, More Tools Register for FREE

Pin to quick picksALM.L Regulatory News (ALM)

  • There is currently no data for ALM

Long Term Incentive Plan

10 May 2016 16:30

RNS Number : 8338X
Allied Minds PLC
10 May 2016
 

 

 

10 MAY 2016

 

Allied Minds plc (the "Company" or the "Group")

 

Long Term Incentive Plan

 

Allied Minds plc, an innovative U.S.-focused science and technology development and commercialisation company, announces that on 09 May 2016 it made conditional awards of 1,499,247 ordinary shares of one pence each ("Ordinary Shares") to certain directors, other persons discharging managerial responsibilities ("PDMRs") and certain other employees under its Long Term Incentive Plan (the "LTIP").

 

Conditional awards in the form of restricted share units have been made to the directors and PDMRs totalling 1,147,290 Ordinary Shares as follows:

 

Director/PDMR

Maximum number of Ordinary Shares conditionally awarded in respect of 2016 LTIP

Maximum number of conditionally awarded Ordinary Shares outstanding at the date of this announcement (including 2016 LTIP)

Chris Silva

238,470

1,763,441

Marc Eichenberger

139,902

1,044,264

Joseph Pignato1

501,636

501,636

Michael Turner

104,186

1,004,464

Omar Amirana

57,418

377,664

John Serafini

49,083

296,519

Peter Dolan (Non-Executive)

15,435

23,605

Richard Davis (Non-Executive)

10,290

15,736

Jeffrey Rohr (Non-Executive)

10,290

15,736

Kevin Sharer (Non-Executive)

10,290

15,736

Jill Smith (Non-Executive)

10,290

10,290

_______________

1 The grant to Joseph Pignato is composed of two parts. Mr. Pignato's 2016 annual grant is 115,762 units and is subject to ordinary vesting conditions through 31 December 2018. Mr. Pignato, who joined the Company in August 2015 as its Chief Financial Officer, was also awarded a new hire grant of 385,874 units under the terms of the LTIP, which was in part compensation for the loss of awards from previous employment. Such grant is also subject to ordinary vesting conditions through 31 December 2018; provided, however, that such new hire grant shall be paid out after the three years ending 31 December 2018 (50%), 2019 (25%) and 2020 (25%).

 

The number of Ordinary Shares stated is the maximum number that could be issued to each director or PDMR upon full satisfaction of the performance conditions attaching to the awards. The awards granted to the non-executive directors are not subject to performance conditions, but instead vest in three equal tranches on the first, second and third anniversaries of grant, subject to the non-executive director continuing to provide services to the Group on the relevant vesting date.

 

In addition to the above, awards in the form of restricted share units over a total of 351,957 Ordinary Shares were made to certain other of the Group's employees pursuant to the 2016 LTIP.

 

The performance conditions attaching to the 2016 awards (other than the non-executive director awards) are based on the achievement of performance metrics measured as follows: 100% of each award will be subject to performance conditions based on the Company's relative total shareholder return (rTSR) performance in respect the period from 01 January 2016 through 31 December 2018. The Company's rTSR will be measured relative to the FTSE 250, the S&P 500, and a peer group of four publicly-traded companies. The Group's Remuneration Policy and Annual Remuneration Report were approved by the Company's shareholders at its Annual General Meeting held on 28 May 2015, and will be again be subject to approval at the Annual General Meeting to be held on 26 May 2016.

 

The awards will vest, to the extent that the performance conditions have been satisfied, on the date following 31 December 2018 on which the extent to which the performance conditions have been satisfied is determined, and the Ordinary Shares will be issued as soon as practicable after such date.

 

As at the date of this announcement, a total of 6,387,170 Ordinary Shares have been conditionally awarded to directors, PDMRs and employees of the Company pursuant to the LTIP and remain subject to performance conditions (other than the non-executive director awards). The Company currently has 215,637,363 Ordinary Shares in issue.

 

About Allied Minds

 

Allied Minds (LSE: ALM) is an innovative U.S. science and technology development and commercialisation company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com.

 

For more information, please contact:

Allied Minds plc

+1 617 419 1800

Chris Silva, Chief Executive Officer

www.alliedminds.com

 

 

Citigate Dewe Rogerson

+44 20 7638 9571

Patrick Donovan/Rob Newman

alliedminds@citigatedr.co.uk

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBUGDULGBBGLG
Date   Source Headline
31st Jan 20173:55 pmRNSTotal Voting Rights
30th Jan 201712:02 pmRNSPrice Monitoring Extension
3rd Jan 20172:48 pmRNSHolding(s) in Company
3rd Jan 20172:11 pmRNSTotal Voting Rights
13th Dec 20167:00 amRNSFormation of Signature Medical, Inc.
9th Dec 20165:04 pmRNSHolding(s) in Company
7th Dec 20164:34 pmRNSHolding(s) in Company
6th Dec 20165:05 pmRNSHolding(s) in Company
6th Dec 20165:04 pmRNSHolding(s) in Company
2nd Dec 20167:00 amRNSResults of equity placing
1st Dec 20164:50 pmRNSProposed Equity Placing
23rd Nov 20167:00 amRNSHawkEye 360 Raises $11m in Series A Financing
21st Nov 20167:00 amRNSFormation of Vatic Materials, Inc.
18th Nov 20163:15 pmRNSBlock Listing Six Monthly Return
11th Nov 20165:17 pmRNSHolding(s) in Company
24th Oct 20167:00 amRNSPrecision Biopsy Raises $5.0 Million
17th Oct 201612:07 pmRNSSecond Price Monitoring Extn
17th Oct 201612:02 pmRNSPrice Monitoring Extension
29th Sep 20167:00 amRNSAllied Minds & GE Ventures Form Strategic Alliance
8th Sep 201612:02 pmRNSPrice Monitoring Extension
31st Aug 20165:11 pmRNSTotal Voting Rights
25th Aug 20167:00 amRNSHalf-year Report
22nd Aug 20167:00 amRNSAllied Minds Secures $20m Debt Facility from SVB
22nd Aug 20167:00 amRNSAllied Minds' Subsidiary ABLS II Raises $15m
1st Aug 20167:00 amRNSSciFluor Enters Clinical Trial Stage
29th Jul 201610:30 amRNSTotal Voting Rights
13th Jul 201610:02 amRNSDirector/PDMR Shareholding
13th Jul 201610:01 amRNSDirector/PDMR Shareholding
13th Jul 201610:01 amRNSDirector/PDMR Shareholding
13th Jul 201610:00 amRNSDirector/PDMR Shareholding
7th Jul 20167:00 amRNSLong Term Incentive Plan - Listing Application
30th Jun 20167:00 amRNSTotal Voting Rights
22nd Jun 20164:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20164:35 pmRNSPrice Monitoring Extension
14th Jun 20162:38 pmRNSDirector/PDMR Shareholding
13th Jun 20165:18 pmRNSDirector/PDMR Shareholding
31st May 20164:44 pmRNSBlocklisting Six Monthly Return
26th May 20165:23 pmRNSResult of AGM
26th May 20167:00 amRNSAGM Statement
25th May 20167:00 amRNSABLS II Completes Drug Feasibility Programme
13th May 20167:00 amRNSDirector/PDMR Shareholding
10th May 20164:30 pmRNSLong Term Incentive Plan
28th Apr 201612:33 pmRNSHolding(s) in Company
26th Apr 20167:00 amRNSAllied Minds Raises $80m for ABLS Capital
25th Apr 20167:00 amRNSAnnual Financial Report
19th Apr 20167:00 amRNSAppointment of Joint Broker
16th Mar 20167:00 amRNSABLS agrees license with NYU
10th Feb 20164:40 pmRNSSecond Price Monitoring Extn
10th Feb 20164:36 pmRNSPrice Monitoring Extension
9th Feb 20164:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.